SCHEMBL4829754

SCHEMBL4829754

COC(=O)COc1ccc(-c2ccc(S(C)(=O)=O)cc2)cc1CCNC(=O)c1cc2ccccc2cc1O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS1 P23219 1/20 0.44
▸ PTGS2 P35354 1/20 0.44
▸ SIRT1 Q96EB6 1/20 0.44
▸ MAPT P10636 5/20 0.43
▸ ALDH1A1 P00352 4/20 0.43
▸ KDM4E B2RXH2 3/20 0.43
▸ CASP1 P29466 1/20 0.43
▸ CASP7 P55210 1/20 0.43
▸ HTT P42858 3/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ MEN1 O00255 3/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ CA12 O43570 3/20 0.39
▸ CA1 P00915 3/20 0.39
▸ CA2 P00918 3/20 0.39
▸ CA9 Q16790 3/20 0.39
▸ NQO2 P16083 1/20 0.38
▸ MTNR1A P48039 1/20 0.38
▸ MTNR1B P49286 1/20 0.38
▸ GAA P10253 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4829624 0.92 ESR1 (0.44) PTGS1PTGS2SIRT1MAPTALDH1A1
SCHEMBL4831735 0.90 PTGS1 (0.48) PTGS1PTGS2SIRT1MAPTALDH1A1
SCHEMBL4829643 0.85 PTGS2 (0.52) PTGS1PTGS2SIRT1MAPTALDH1A1
SCHEMBL6504452 0.81 CA12 (0.45) MAPTALDH1A1KDM4EHTTMEN1
SCHEMBL4832092 0.76 MAPT (0.48) PTGS1PTGS2SIRT1MAPTALDH1A1
SCHEMBL4829844 0.71 KDM4E (0.55) PTGS1PTGS2SIRT1MAPTALDH1A1
SCHEMBL4831515 0.69 MAPT (0.67) PTGS1PTGS2SIRT1MAPTALDH1A1
SCHEMBL8339590 0.68 MAPT (0.63) PTGS1PTGS2SIRT1MAPTALDH1A1
SCHEMBL6504449 0.67 KDM4E (0.40) PTGS2MAPTALDH1A1KDM4ESMN1; SMN2
SCHEMBL11439147 0.66 MAPT (0.84) PTGS1PTGS2SIRT1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459472-B2 Aryl and heteroaryl compounds, compositions, and methods of use TRANSTECH PHARMA, INC. (US) 2008-12-02 — — US disclosed
US-20050059713-A1 Aryl and heteroaryl compounds, compositions, and methods of use VTVX HOLDINGS I LLC 2005-03-17 — — US disclosed
WO-2005014534-A1 ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE TRANSTECH PHARMA, INC. (US) 2005-02-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059713-A1 Aryl and heteroaryl compounds, compositions, and methods of use CYP2F1, CYP3A43, PNPO PTGS1 3399/4885PTGS2 3634/4885SIRT1 4149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback